Rapid detection of <i>Mycoplasma pneumonia</i> in a microfluidic device using immunoagglutination assay and static light scattering

Kim, Keesung; Jung, Ho‐Sup; Song, Jae-Young; Lee, Man Ryul; Kim, Kye-Seong; Suh, Kune Y.

doi:10.1002/elps.200900136

Cited by 10 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional assay methods used for diagnosis of the pulmonary disease primarily include spirometry, cell migration assay, 9 acid fast smear using sputum, 12 gene expression analysis, 15 cell culture assays, [16][17] interferon gamma release assay. 18 In addition, for understanding the mechanism of pulmonary diseases, researchers have conducted their studies conventionally in human patients, 9 animal models, 4,14 and using in vitro lung tissue slices.…”

Section: Conventional Study Models and Diagnostic Methodsmentioning

confidence: 99%

“…12 Gene expression analysis Laborious, samples are subjected to considerable ex-vivo perturbation resulting in documented phenotypic and functional changes. 15 Cell culture assay Unable to mimic the in vivo conditions, 16,17 contamination is a big challenge. 17 Interferon gamma release assay Unable to count the number of CD4 cells secreting the cytokine, that makes them less accurate.…”

Section: Conventional Diagnostic Methods Shortcomingsmentioning

confidence: 99%

“…15 Cell culture assay Unable to mimic the in vivo conditions, 16,17 contamination is a big challenge. 17 Interferon gamma release assay Unable to count the number of CD4 cells secreting the cytokine, that makes them less accurate. …”

Section: Conventional Diagnostic Methods Shortcomingsmentioning

confidence: 99%

See 2 more Smart Citations

Revisiting Pulmonary Diseases using Microfluidic Technology

Anjali

Poddar

Mahto

2016

IJBSBE

View full text Add to dashboard Cite

Pulmonary diseases such as chronic obstructive pulmonary disease, asthma and tuberculosis are among the leading causes of death globally, accounting for nearly 4 million of all deaths worldwide every year. Prevention, management and treatment of these deadly diseases require early detection of pathogens and accurate study of pathophysiology of the respiratory system. In recent years, microfluidic technology has emerged as a powerful tool for recapitulation of the physiological and pathological scenarios of the lung for enhancing the current understanding of pulmonary disorders. This review paper outlines the advantages of microfluidic devices in providing improved insights into the mechanism of the pulmonary diseases, identification of their novel biomarkers and the development of new and advanced therapeutic strategies. Furthermore, several microfluidic lung models are discussed along with progresses made from the aboriginal to till date.

show abstract

Section: Conventional Study Models and Diagnostic Methodsmentioning

confidence: 99%

Section: Conventional Diagnostic Methods Shortcomingsmentioning

confidence: 99%

See 1 more Smart Citation

Revisiting Pulmonary Diseases using Microfluidic Technology

Anjali

Poddar

Mahto

2016

IJBSBE

View full text Add to dashboard Cite

show abstract

“…Conventional assay methods used for diagnosis of the pulmonary disease primarily include spirometry, cell migration assay [9], acid fast smear using sputum [12], gene expression analysis [15], cell culture assays [16][17], interferon gamma release assay [18]. In addition, for understanding the mechanism of pulmonary diseases, researchers have conducted their studies conventionally in human patients [9], animal models [4], [14] and using in vitro lung tissue slices [16].…”

Section: Conventional Study Models and Diagnostic Methodsmentioning

confidence: 99%

Untitled

2016

IJBSBE

View full text Add to dashboard Cite

Revisiting Pulmonary Diseases using Microfluidic IntroductionThe human respiratory system consists of nose, pharynx (throat), larynx (voice box), trachea (windpipe), bronchi, and the lungs [1]. The nose, pharynx, larynx, trachea and bronchi together form the respiratory airways. The bronchus continues to divide within lung into many narrower and shorter airways known as bronchioles [2]. The branching networks of pulmonary airways are lined with a viscous liquid film secreted by airway epithelial cells [3]. Terminal bronchioles are clustered in grapelike sacs, the alveoli. Gaseous exchange between air and blood takes place in the alveoli. The lungs contain approximately 500 million alveoli, each about 200 to 300 μm in diameter. The alveolar wall consists of a single layer of type I alveolar cells. Each alveolus is surrounded by a network of pulmonary capillaries. The interstitial space between pulmonary capillaries and alveolus forms a very thin barrier which facilitates gaseous exchange. Apart from type I alveolar cells, 5 % of the alveolar surface epithelium is covered by type II alveolar cells, which secrete a phosphor lipoprotein complex known as pulmonary surfactant that facilitates lung expansion [2]. In addition to type II alveolar cells, surfactant proteins are also produced by Clara cells of peripheral airways. The pulmonary surfactant produced from these cells is absorbed into the luminal air-liquid interface of the pulmonary airways and thus reduces the surface tension to values as low as zero during expiration. This in turn prevents the airway closure [4]. Lung epithelium is a highly complex tissue where epithelial cells, sub epithelial fibroblasts and the extracellular matrix of the airway wall are intricately involved in maintaining and regulating the structure and function of the lung [5]. Lung diseasesRespiratory diseases and disorders encompass pathological conditions that mostly affect the organs and tissues that take part in gaseous exchange (Figure 1). Notably, such abnormalities affect the airways, the physiology structure of lung tissue, and the pulmonary circulation [6]. The lung diseases are broadly classified into obstructive, restrictive and infectious diseases (Table 1).Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the world. The COPD burden is projected to increase globally in the coming decades because of continued exposure to COPD risk factors and aging of the population [7]. COPD, a chronic inflammatory disease, is generally an adult age problem [8] and characterized by breathing difficulty as a consequence of narrowed airways. Long term exposure of lungs to noxious particles or gases, such as cigarette smoke, is considered as the main cause of COPD. According to WHO, COPD will become third leading cause of death by 2030 [9].Similarly, asthma is also amongst the chronic inflammatory disorders characterized by active hyper responsiveness to a variety of stimuli e.g. airborne allergens. It results from a complex interaction among inflammatory cel...

show abstract

“…Although there have been a number of optical approaches with microfluidic devices including surface enhanced Raman scattering, interferometry, and particle beam emission spectroscopy [12][13][14], little effort has been made Keesung Kim 1,2 Man-Bock Gu toward the development of light scattering detection inside a microfluidic device [15,16]. In this sense, the so-called ''light scattering particle immunoagglutination assay'' (LSPIA) could be a new, alternative method for rapid and high-sensitivity detection of proteins, viruses and bacteria [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

High‐sensitivity detection of oxytetracycline using light scattering agglutination assay with aptasensor

Kim

Kang

et al. 2010

Electrophoresis

Self Cite

View full text Add to dashboard Cite

We present an aptamer-based biosensor (aptasensor) for rapid and high-sensitive detection of oxytetracycline (OTC) antibiotic in PBS inside a Y-channel PDMS microfluidic device. The detection was made by real-time monitoring of the agglutination assay of ssDNA aptamer-conjugated polystyrene latex microspheres with proximity optical fibers. The agglutination assay was performed with serially diluted OTC antibiotic solutions using highly carboxylated polystyrene particles of 920 nm diameter conjugated with OTC-binding ssDNA aptamer. Proximity optical fibers were used to measure the increase in 45° forward light scattering of the aggregated particles by fixing them around the viewing cell of the device with stable angle and distance to the detector. The detection limit was around 100 ppb for the current aptasensor system with the detection time less than 3 min.

show abstract

Rapid detection of Mycoplasma pneumonia in a microfluidic device using immunoagglutination assay and static light scattering

Cited by 10 publications

References 30 publications

Revisiting Pulmonary Diseases using Microfluidic Technology

Revisiting Pulmonary Diseases using Microfluidic Technology

Untitled

High‐sensitivity detection of oxytetracycline using light scattering agglutination assay with aptasensor

Contact Info

Product

Resources

About